PPT-Nuclear Medicine procedures in prostate cancer: from diagnosis to treatment

Francesco GIAMMARILE   Aut tace aut loquere meliora silentio   Bone scan and FCholine Radionuclide treatment Presentation Outline Introduction NO CONFLICT OF INTEREST General aspects. Matthew D. Katz, M.D.. Assistant Professor. Urologic Oncology . Robotic and Laparoscopic Surgery. University of Arkansas for Medical Sciences. Winthrop P. Rockefeller Cancer Center. Anatomy Genitourinary System. Alexandre . Iscaife. ; Denis Reis Morais; Sabrina Thalita Reis; Nayara Izabel Viana, . Andre. . Bordini. ; Daniele . Janolli. ; Nelson . Dip. ; Miguel . Srougi. ; Katia Ramos Moreira Leite . Laboratory of Medical Research – LIM 55, Urology, University of Sao Paulo, Sao Paulo, Brazil. CÉSAR DAVID VERA-DONOSO. Department. of . Urology. WHO IS IN THE LINE OF FIRE?. WE NEED TO COLLABORATE IN MANY FIELDS. WE NEED RELIABLE IMAGES TO TAKE DECISIONS. INCIDENCE. EUROPE. In Europe, . PCa. PUBLICATIONS Peer Reviewed Articles, Turmen T: Congenital posterolateral diaphragmatic hernia. , Turmen T: Necrotizing enterocolitis. CLINICS OF TURKEY pendicitis with situs inversus totalis closel PUBLICATIONS Peer Reviewed Articles Turmen T Congenital posterolateral diaphragmatic hernia Turmen T Necrotizing enterocolitis CLINICS OF TURKEY pendicitis with situs inversus totalis closely mimicki 1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, et al. JAMA . Oncol. . 2015; 1(4): 505-27/ 2. . Droz. JP, et al. Lancet . Oncol. . 2014; 15(9): e404-14/ 3. . Cuzick. J, et al. Lancet . 1 Brachytherapy Treatment for Prostate Cancer One of the side effects is erectile dysfunction. It may not be suitable for men who already have urinary problems. Urinary problems such as incontinenc 279 in Mexico, PC prevalence and the consequent impact of PSA screening cannot be accurately measured. Multiple fundamental prognostic factors for PC (among othershave been considered: 1. PSA determin Investigations for Prostate cancer Presentation: Diagnosis: Risk stratification (Ref) : Low risk PSA 0, Gleason score 6 (ISUP 1), DRE showing cT1 - T2a Intermediate risk: PSA 10 - 20, Sorting Out the Androgen Deprivation Therapy Options for Locally Advanced . CSPC. Supported by an educational grant from Astellas and Pfizer, Inc.. EPISODE 3. Cora N. Sternberg MD, FACP. Clinical Director, . Victoria . Sinibaldi. , RN, MS, CS, CANP, BC. Daniel P . Petrylak. , MD. . Disclosures for . Ms. . Sinibaldi. No financial interests or affiliations to disclose. Disclosures for Dr . Petrylak. Consulting Agreements. By: Ishan Parikh. Symptoms. Be on the look out for…. “stop-and-go” flow of urine. Sudden urges to urinate. Frequent urination (esp. at nights). Trouble starting urination. Trouble with emptying bladder completely. Dr Marie-Pier St-Laurent, MD, FRCSC. Urologic-Oncology fellow, UBC. Research scientist, Vancouver Prostate Centre. Honorarium: Bayer, PCSC. As a urologist, I am biased towards prostate cancer screening.. NASPCC 10-13-18. Ronald Chen, MD MPH. Associate Professor, Radiation Oncology. University of North Carolina – Chapel Hill. Associate Director, UNC Lineberger Comprehensive Cancer Center. Disclosures.